Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 22;11(19):5559.
doi: 10.3390/jcm11195559.

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?

Fabrice Camou  1 , Nahéma Issa  1   2 , Mojgan Hessamfar  2 , Olivier Guisset  1 , Gaëlle Mourissoux  1 , Stéphane Pedeboscq  3 , Aimée Minot  3 , Fabrice Bonnet  2   4
Affiliations

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?

Fabrice Camou et al. J Clin Med. .

Abstract

Background: Dexamethasone and tocilizumab are used to treat severely ill COVID-19 patients admitted to intensive care units (ICUs). We explored whether combination therapy increased the risk of superinfection compared to dexamethasone alone.

Methods: This observational, retrospective study included critically ill COVID-19 adult patients admitted to our ICU because of respiratory failure. Patients received dexamethasone with (Group 1) or without (Group 2) tocilizumab. Data were collected from electronic medical files.

Results: A total of 246 patients were included, of whom 150 received dexamethasone and tocilizumab, while 96 received dexamethasone alone. Acute respiratory distress syndrome was evident on admission in 226 patients, 56 of whom required mechanical ventilation (MV). Superinfections, mainly respiratory, were diagnosed in 59 patients, including 34/150 (23%) in Group 1 and 25/96 (26%) in Group 2 (p = 0.32). After multivariate analysis, the factors associated with a higher risk of superinfection included hematological malignancy (hazard ratio (HR): 2.47 (1.11-5.47), p = 0.03), MV (HR: 3.74 (1.92-7.26), p = 0.0001), and a higher SAPS-II score on admission (HR: 1.03 (1.01-1.06), p = 0.006).

Conclusion: In critically ill COVID-19 patients, the addition of tocilizumab to dexamethasone was not associated with an increased risk of superinfection.

Keywords: COVID-19; dexamethasone; superinfection; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Gordon A.C., Mouncey P.R., Al-Beidh F., Rowan K.M., Nichol A.D., Arabi Y.M., Annane D., Beane A., Van Bentum-Puijk W., Berry L.R., et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N. Engl. J. Med. 2021;384:1491–1502. doi: 10.1056/nejmoa2100433. - DOI - PMC - PubMed
    1. Bhimraj A., Morgan R.L., Shumaker A.H., Baden L., Cheng V.C.C., Edwards K.M., Gallagher J.C., Gandhi R.T., Muller W.J., Nakamura M.M., et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. [(accessed on 23 August 2022)]. Available online: https://www.idsociety.org. - PubMed
    1. Grasselli G., Scaravilli V., Mangioni D., Scudeller L., Alagna L., Bartoletti M., Bellani G., Biagioni E., Bonfanti P., Bottino N., et al. Hospital-Acquired Infections in Critically Ill Patients with COVID-19. Chest. 2021;160:454–465. doi: 10.1016/j.chest.2021.04.002. - DOI - PMC - PubMed
    1. Lamouche-Wilquin P., Souchard J., Pere M., Raymond M., Asfar P., Darreau C., Reizine F., Hourmant B., Colin G., Rieul G., et al. Early steroids and ventilator-associated pneumonia in COVID-19-related ARDS. Crit. Care. 2022;26:233. doi: 10.1186/s13054-022-04097-8. - DOI - PMC - PubMed
    1. Søvik S., Barratt-Due A., Kåsine T., Olasveengen T., Strand M.W., Tveita A.A., Berdal J.E., Lehre M.A., Lorentsen T., Heggelund L., et al. Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. J. Infect. 2022;85:57–63. doi: 10.1016/j.jinf.2022.05.015. - DOI - PMC - PubMed

LinkOut - more resources